In 2021, the FDA approved atezolizumab as an additional treatment following adjuvant chemotherapy for patients with completely resected stage II–IIIA non-small-cell lung cancer (NSCLC) and PD-L1 expression on ≥1% of tumour cells, based on data from the phase III IMpower010 trial. Now, data from the phase III PEARLS/KEYNOTE-091 trial demonstrate broader benefit from adjuvant pembrolizumab for early stage NSCLC.